3. Pregnancy is associated with a 30 to 50
percent increase in cardiac output and a 40 to
50 percent increase in maternal blood volume
over baseline values.
The cardiac output gradually increases
through the first trimester and reaches a peak
at approximately 20 to 24 weeks of gestation;
the high output state is then maintained
throughout the remainder of pregnancy
4. The resting transmitral gradient increases by
the square of the cardiac output.
In general, the patient’s symptomatic status
during pregnancy will increase by about one
NYHA class
5. During active labor, additional increases in
cardiac output and stroke volume occur with
each uterine contraction (additional 50 percent)
Following delivery, there is an abrupt increase in
preload, resulting from the autotransfusion of
uterine blood into the systemic circulation and
to aortal caval decompression in the absence of
a gravid uterus.
The increase in cardiac output can persist up to
six weeks postpartum and can continue to
exaggerate the adverse hemodynamic effects of
MS
6. Women with MS should be evaluated before
pregnancy to determine the need for
prophylactic percutaneous mitral balloon
valvotomy (PMBV) or surgical intervention
7. Mild to moderate MS
can almost always be managed with judicious use
of diuretics and beta blockade
Though diuretics are safe during pregnancy,
care must be taken to avoid hypovolemia
A beta blocker should be tried, beginning
with very low doses. A cardioselective drug
may be preferred
8. Who fail medical management should
undergo PMBV at experienced centers
In developing regions where PMBV may not
be available, surgical closed
commissurotomy has been successfully
performed in pregnant women
The preferred time for PMBV is in the 22 to 26
week gestational window that minimizes the
radiation risks to the developing fetus
9. If a pregnant woman becomes hemodynamically
unstable with AF, electrical cardioversion is both safe
and effective.
If an antiarrhythmic drug is needed to maintain sinus
rhythm because of poorly tolerated symptoms with AF,
quinidine and procainamide are the drugs of choice
Beta blockers are preferred for control of the
ventricular rate.
Anticoagulation should be continued during
pregnancy.
Warfarin is typically avoided in the first trimester
because of its known teratogenic effects, particularly
between the sixth and ninth weeks
10. For women with severe mitral stenosis or
symptoms of heart failure at the time of
labor, invasive hemodynamic monitoring with
a right heart catheter is appropriate
11. Routine endocarditis prophylaxis is
not necessary for either cesarean or vaginal
delivery
However, continuation of antibiotics for
secondary prophylaxis of rheumatic fever is
recommended